FDA-CMS Parallel Reviews: Too Close for Comfort?

Parallel reviews by FDA and CMS are back on the table. While the proposed voluntary program seems harmless enough, drug and biotech companies may have good reason to be wary of greater collaboration between FDA and CMS officials.